Schistosomiasis and Strongyloidiasis Recommendations for Solid-Organ Transplant Recipients and Donors

Transplantation. 2018 Feb;102(2S Suppl 2):S27-S34. doi: 10.1097/TP.0000000000002016.

Authors

Luis Fernando A Camargo¹, Nassim Kamar², Eduardo Gotuzzo³, Alissa Jade Wright⁴

Affiliations

¹ Hospital Israelita Albert Einstein, São Paulo, Brazil.
² Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
³ Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
⁴ Transplant Infectious Disease and Compromised Host Program, Massachusetts General Hospital, Boston, MA.

PMID: 29381575
DOI: 10.1097/TP.0000000000002016

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antinematodal Agents / adverse effects
Antinematodal Agents / therapeutic use*
Antiplatyhelmintic Agents / adverse effects
Antiplatyhelmintic Agents / therapeutic use*
Donor Selection / methods*
Donor Selection / standards
Host-Parasite Interactions
Humans
Immunocompromised Host
Immunosuppressive Agents / adverse effects
Organ Transplantation / adverse effects
Organ Transplantation / methods*
Organ Transplantation / standards
Practice Guidelines as Topic
Risk Assessment
Risk Factors
Schistosoma / drug effects*
Schistosoma / isolation & purification
Schistosoma / pathogenicity
Schistosomiasis / diagnosis
Schistosomiasis / drug therapy*
Schistosomiasis / parasitology
Schistosomiasis / transmission
Strongyloides / drug effects*
Strongyloides / isolation & purification
Strongyloides / pathogenicity
Strongyloidiasis / diagnosis
Strongyloidiasis / drug therapy*
Strongyloidiasis / parasitology
Strongyloidiasis / transmission
Tissue Donors*
Transplant Recipients*
Treatment Outcome

Substances

Antinematodal Agents
Antiplatyhelmintic Agents
Immunosuppressive Agents